Most types of breast cancer produce similar symptoms and are discovered the same way—finding a strange new lump during a self-exam, or a healthcare provider spotting something suspicious during a ...

Breast cancer refers to the uncontrolled growth of epithelial cells originating from the ducts or lobules. The malignancy is initially characterized by a painless lump, followed by swelling, itching, ...

At the Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit, an expert explained HER2-positive breast cancer and gave an overview of effective treatment options in this space.

HER2-positive breast cancers have more HER2 receptors and can grow and spread faster than HER2-negative cancers. HER2 status should be tested regularly as it can change if the cancer recurs or spreads ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE ®) to current standard-of-care ...

The approval came exactly 2 months after results from the landmark DESTINY-Breast04 trial showed that the antibody drug conjugate reduced the risk of disease progression or death by 50% compared with ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients ...

- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 ...